Amgen stock draws attention after a Phase 3 trial win
Published on 09/29/2026 at 10:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen (ISIN US0311621009) was last at USD 418.13 on Nasdaq on September 28, 2026 at 4:00 p.m. ET, with a daily change of 0.85 percent. The latest clinical catalyst came on September 22, when Amgen reported positive topline Phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease.
Dazodalibep clears a pivotal test
Amgen said the OASIZ 301 study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in ESSDAI at Week 48. The company also reported that improvement appeared from Week 4 and continued through Week 48, giving the program a measurable duration signal alongside the headline result.
The readout strengthens Amgen's autoimmune pipeline narrative, but the commercial case still depends on detailed efficacy, secondary-endpoint and regulatory data. The positive result is therefore important as a development milestone rather than a reported revenue contribution.
Q2 revenue rises 10 percent
According to TradingView, Amgen generated USD 10.05 billion of revenue in Q2 2026, up 10 percent from Q2 2025. GAAP diluted EPS reached USD 4.37, while non-GAAP diluted EPS was USD 6.29 and free cash flow totaled USD 3.489 billion.
That operating comparison gives the trial result financial context: Amgen entered the September pipeline update with double-digit quarterly revenue growth and multiple products expanding sales. At the same time, patent erosion and competitive pressure on established medicines remain important factors in how much value investors assign to new assets.
Valuation stays below the latest price
A Simply Wall St model raised its fair value estimate from USD 371.93 to USD 388.03 in an update dated September 19, 2026. The new estimate remained below Amgen's September 28 price, placing the clinical catalyst alongside a valuation debate rather than a single directional signal.
Amgen stock holds a large market value
Amgen stock was last at USD 418.13 on Nasdaq on September 28, 2026 at 4:00 p.m. ET. The stock's 52-week range was USD 270.67 to USD 447.03, market capitalization was USD 225.7 billion and volume was 2,629,033 shares.
Amgen stock snapshot
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: AMGN
- Trading venue: Nasdaq
- Price (as of September 28, 2026, 4:00 p.m. ET): USD 418.13
- Market capitalization: USD 225.7 billion (as of September 28, 2026)
- 52-week range: USD 270.67-447.03 (as of September 28, 2026)
- Sector / Industry: Biotechnology
